Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition
Bob T. Li(Memorial Sloan Kettering Cancer Center), Yi‐Long Wu(Guangdong General Hospital), Craig Tendler(Johnson & Johnson (United States)), Bruce A. Chabner(Massachusetts General Hospital), Monica M. Bertagnolli(Brigham and Women's Hospital), Tinghui Wu(National Taiwan University), R. Angelo de Claro(United States Food and Drug Administration), Kevin Rudd(Asia Society), Robert LaCaze(Bayer (Germany)), Karen Kaucic, Jennifer S. Mills(Foundation Medicine (United States)), Mark Junjie Li(Agilent Technologies (United States)), Martin J. Murphy(Virginia Commonwealth University), Phuong K. Morrow(The University of Texas MD Anderson Cancer Center), Charles S. Fuchs(Yale Cancer Center), Richard Pazdur(United States Food and Drug Administration), Javad Shahidi(Daiichi Sankyo (United States)), Jing Qian(Asia Society), Eduard Gasal, Mary Gospodarowicz(University of Toronto), Elizabeth Franklin(Cancer Support Community), Björn Albrecht(McKinsey & Company (United States)), Otis W. Brawley(American Cancer Society), Justin Finnegan(Bloomberg (United States)), Lola A. Fashoyin‐Aje(Center for Drug Evaluation and Research), Geoffrey Kim(United States Food and Drug Administration), Stefan Oelrich(Bayer (Germany)), James Yan, Yi Shao(Second Hospital of Tianjin Medical University), Bobby Daly(Memorial Sloan Kettering Cancer Center), Lianshan Zhang(Jiangsu Hengrui Medicine (China)), Lydia Thé(McKinsey & Company (United States)), Jeff Legos(Novartis (Switzerland)), Tina Hou(McKinsey & Company (United States))
Cited by 52
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k